Valuation: Jasper Therapeutics, Inc.

Market Cap 19.86M 17.18M 16.05M 14.72M 27.69M 1.89B 28.13M 188M 73.89M 948M 74.59M 72.96M 3.13B P/E 2026 *
-0.8x
P/E 2027 * -0.56x
Enterprise Value -263M -227M -212M -195M -366M -24.98B -372M -2.49B -976M -12.52B -986M -964M -41.4B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.44%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jasper Therapeutics, Inc.

1 day+9.81%
1 week+12.62%
Current month+12.62%
1 month+37.87%
3 months-23.40%
6 months-47.44%
Current year-61.23%
1 week 0.59
Extreme 0.59015
0.75
1 month 0.54
Extreme 0.54141
1.03
Current year 0.32
Extreme 0.3151
2.07
1 year 0.32
Extreme 0.3151
3.14
3 years 0.32
Extreme 0.3151
31.01
5 years 0.32
Extreme 0.3151
188.8
10 years 0.32
Extreme 0.3151
188.8
Manager TitleAgeSince
Chief Executive Officer 54 06/01/2026
Director of Finance/CFO 54 22/09/2023
Chief Operating Officer 59 16/07/2026
Director TitleAgeSince
Director/Board Member 54 06/01/2026
Director/Board Member 70 04/09/2021
Director/Board Member 58 24/09/2021
Date Insider Type Main position Quantity % Market Cap.
31/07/26 Free

Founder

7,500 0.0268%
31/07/26 Free

Director

7,500 0.0268%
31/07/26 Free

Chairman

7,500 0.0268%
Change 5-day change 1-year change 3-year change Capi.($)
+9.81%+12.62%-71.04%-95.17% 19.86M
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +4.44%+11.78%+41.49%+177.34% 26.36B
Weighted average by Cap. +4.36%+13.10%+50.68%+168.45%

Financials

2026 *2027 *
Net sales - -
Net income -36.99M -32M -29.88M -27.41M -51.55M -3.52B -52.37M -351M -138M -1.76B -139M -136M -5.83B -64.38M -55.69M -52M -47.7M -89.73M -6.13B -91.15M -610M -239M -3.07B -242M -236M -10.15B
Net Debt -282M -244M -228M -209M -394M -26.87B -400M -2.68B -1.05B -13.47B -1.06B -1.04B -44.53B -555M -480M -448M -411M -773M -52.78B -785M -5.26B -2.06B -26.46B -2.08B -2.04B -87.46B
Logo Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the c-Kit receptor, inhibiting signaling for mast cells and a maintenance signal for hematopoietic stem cells. KIT inhibition with briquilimab has demonstrated clinical outcomes both as a conditioning agent for stem cell transplant in SCID and Fanconi anemia. Its pipeline also includes KP-104 (vensobafusp alfa), a bifunctional complement inhibitor in clinical development, and KP-701, a preclinical B-cell receptor-targeted therapy.
Employees
22
Date Price Change Volume
07/08/26 $0.7095 +9.81% 760,645
06/08/26 $0.6461 -2.09% 650,929
05/08/26 $0.6599 -0.84% 336,421
04/08/26 $0.6655 +9.76% 718,807
03/08/26 $0.6063 -3.76% 322,164
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
0.7095USD
Average target price
9.167USD
Spread / Average Target
+1,191.99%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JSPR Stock